AAP
DMIIR

Arax Advisory Partners’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Arax Advisory Partners’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.28K Buy
+65,990
New +$5.64K ﹤0.01% 4577

Other funds holding DMIIR

CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Arax Advisory Partners's DMIIR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Drugs Made In America Acquisition II Corp Right (DMIIR) in Q2 2026: 65,990 shares worth $5.28K. The stake represents ﹤0.01% of the portfolio and ranks #4577 among its holdings.

7 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Arax Advisory Partners held 65,990 shares of Drugs Made In America Acquisition II Corp Right worth $5.28K as of Q2 2026.
  • Drugs Made In America Acquisition II Corp Right was a new Arax Advisory Partners position in Q2 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4577 holding.
  • 7 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.